Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Juni 2018 07:00 ET | Quelle: FibroGen, Inc

FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease

SAN FRANCISCO, June 07, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the...
04. Juni 2018 14:05 ET | Quelle: FibroGen, Inc

FibroGen to Present at Two Upcoming Investor Conferences

SAN FRANCISCO, June 04, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that management will participate in a Fireside Chat at the Jefferies 2018...
03. Juni 2018 21:30 ET | Quelle: FibroGen, Inc

FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting

SAN FRANCISCO, June 03, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced Phase 1/2 clinical trial results of pamrevlumab in combination with...
21. Mai 2018 16:00 ET | Quelle: FibroGen, Inc

FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018

SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that updated results from the company’s randomized, double-blind,...
09. Mai 2018 16:02 ET | Quelle: FibroGen, Inc

FibroGen Reports First Quarter 2018 Financial Results

Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00...
02. Mai 2018 07:00 ET | Quelle: FibroGen, Inc

FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018

SAN FRANCISCO, May 02, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report first quarter 2018 financial results on...
01. März 2018 13:45 ET | Quelle: FibroGen, Inc

UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer

SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
01. März 2018 07:00 ET | Quelle: FibroGen, Inc

Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer

SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
27. Februar 2018 16:11 ET | Quelle: FibroGen, Inc

FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results

Roxadustat U.S. Phase 3 Program in CKD Anemia Enrollment Completion and Data Readout in 2018 Pamrevlumab Phase 2 IPF Study Achieves Statistically Significant Attenuation of Lung Fibrosis as Measured...
21. Februar 2018 07:00 ET | Quelle: FibroGen, Inc

FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018

SAN FRANCISCO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report fourth quarter and full year 2017...

Vorherige Seite